Breaking News


Topical tacrolimus and efficacy of narrowband UVB therapy in vitiligo


A prospective, single-blind study of tacrolimus 0.1% ointment was conducted in 80 patients aged 12-42 years with facial, trunk or limb vitiligo. The tacrolimus was applied on lesions on the left side of the body and no agent on corresponding lesions on the right side. Patients also received narrowband-ultraviolet B (NB-UVB) therapy three times a week for up to 12 months or until complete repigmentation of study lesions, if this occurred earlier. The extent of repigmentation was based on a 0-6 Vitiligo Area Scoring Index (VASI), where a score of 6 equaled 100% repigmentation. Of the 80 patients, 74 completed the study. The mean repigmentation score was 71% (VASI = ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list